Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.15%AUDUSD-1.11%GBPCHF+1.02%USDCHF+0.96%GBPCAD+0.78%GBPNZD+0.78%NZDUSD-0.75%USDCAD+0.75%EURGBP-0.66%GBPJPY+0.64%EURUSD-0.62%USDJPY+0.59%USDTHB+0.58%AUDJPY-0.54%EURAUD+0.51%PLNJPY+0.44%GBPTRY+0.41%SGDJPY+0.39%AUDCAD-0.39%AUDNZD-0.36%EURCHF+0.33%CHFJPY-0.33%NOKJPY+0.32%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%CADCHF+0.22%NZDCHF+0.21%AUDNOK+0.21%USDNOK+0.18%NZDMXN-0.18%AUDCHF-0.18%USDILS+0.16%EURNZD+0.14%NZDJPY-0.14%CADJPY-0.14%AUDSGD+0.13%EURCAD+0.12%USDSGD+0.11%USDCNH-0.11%EURNOK+0.11%NZDSGD-0.10%CHFNOK+0.10%AUDDKK+0.10%EURHKD-0.10%USDZAR+0.10%USDSEK+0.09%USDDKK+0.08%USDPLN+0.07%USDMXN+0.06%GBPUSD+0.04%USDCOP-0.04%EURSGD+0.03%USDHKD+0.03%EURJPY-0.03%CHFSGD+0.03%EURCZK+0.03%GBPSGD+0.02%CHFSEK+0.01%EURSEK+0.01%EURZAR+0.01%NZDCAD-0.01%EURPLN0.00%GBPZAR0.00%EURCNH0.00%EURDKK0.00%USOIL-1.41%GAGUSD+1.28%XAGUSD+1.28%UKOIL-1.17%S1-0.62%XNGUSD-0.59%XAUUSD+0.50%GAUUSD+0.50%XPTUSD+0.44%HG1-0.39%C1-0.37%COTTON-0.35%BTCUSD+0.57%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.92%ZECUSDT+1.58%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.39%XLMUSD+3.07%BCHUSDT+0.53%UNIUSD+1.15%LTCUSD+0.07%HBARUSDT+4.15%SUIUSD+2.05%TONUSD+15.77%TAOUSDT+2.72%AAVEUSD+0.86%DOTUSDT+4.63%ICPUSDT-1.17%ONDOUSDT+2.03%WLDUSDT+9.89%ARBUSDT+1.53%JUPUSDT+0.41%ATOMUSDT+2.73%INJUSDT-0.40%STXUSDT+25.59%FETUSDT+5.52%SEIUSDT+1.69%PYTHUSDT-0.17%TIAUSDT+2.65%IMXUSDT+3.40%GRTUSDT+2.07%OPUSDT+2.09%WIFUSDT+4.29%IOTAUSDT+7.44%POLUSDT-3.39%AXSUSDT+1.28%FARTCOINUSDT+0.50%EOSUSDT+4.55%DYDXUSDT+5.13%GALAUSDT+3.85%ORDIUSDT+2.69%NOTUSDT+2.57%RONINUSDT+3.21%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.15%AUDUSD-1.11%GBPCHF+1.02%USDCHF+0.96%GBPCAD+0.78%GBPNZD+0.78%NZDUSD-0.75%USDCAD+0.75%EURGBP-0.66%GBPJPY+0.64%EURUSD-0.62%USDJPY+0.59%USDTHB+0.58%AUDJPY-0.54%EURAUD+0.51%PLNJPY+0.44%GBPTRY+0.41%SGDJPY+0.39%AUDCAD-0.39%AUDNZD-0.36%EURCHF+0.33%CHFJPY-0.33%NOKJPY+0.32%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%CADCHF+0.22%NZDCHF+0.21%AUDNOK+0.21%USDNOK+0.18%NZDMXN-0.18%AUDCHF-0.18%USDILS+0.16%EURNZD+0.14%NZDJPY-0.14%CADJPY-0.14%AUDSGD+0.13%EURCAD+0.12%USDSGD+0.11%USDCNH-0.11%EURNOK+0.11%NZDSGD-0.10%CHFNOK+0.10%AUDDKK+0.10%EURHKD-0.10%USDZAR+0.10%USDSEK+0.09%USDDKK+0.08%USDPLN+0.07%USDMXN+0.06%GBPUSD+0.04%USDCOP-0.04%EURSGD+0.03%USDHKD+0.03%EURJPY-0.03%CHFSGD+0.03%EURCZK+0.03%GBPSGD+0.02%CHFSEK+0.01%EURSEK+0.01%EURZAR+0.01%NZDCAD-0.01%EURPLN0.00%GBPZAR0.00%EURCNH0.00%EURDKK0.00%USOIL-1.41%GAGUSD+1.28%XAGUSD+1.28%UKOIL-1.17%S1-0.62%XNGUSD-0.59%XAUUSD+0.50%GAUUSD+0.50%XPTUSD+0.44%HG1-0.39%C1-0.37%COTTON-0.35%BTCUSD+0.57%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.92%ZECUSDT+1.58%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.39%XLMUSD+3.07%BCHUSDT+0.53%UNIUSD+1.15%LTCUSD+0.07%HBARUSDT+4.15%SUIUSD+2.05%TONUSD+15.77%TAOUSDT+2.72%AAVEUSD+0.86%DOTUSDT+4.63%ICPUSDT-1.17%ONDOUSDT+2.03%WLDUSDT+9.89%ARBUSDT+1.53%JUPUSDT+0.41%ATOMUSDT+2.73%INJUSDT-0.40%STXUSDT+25.59%FETUSDT+5.52%SEIUSDT+1.69%PYTHUSDT-0.17%TIAUSDT+2.65%IMXUSDT+3.40%GRTUSDT+2.07%OPUSDT+2.09%WIFUSDT+4.29%IOTAUSDT+7.44%POLUSDT-3.39%AXSUSDT+1.28%FARTCOINUSDT+0.50%EOSUSDT+4.55%DYDXUSDT+5.13%GALAUSDT+3.85%ORDIUSDT+2.69%NOTUSDT+2.57%RONINUSDT+3.21%
TT

Travere Therapeutics, Inc. (TVTX)

NASDAQ • Healthcare

$58.88
-$1.1 (-1.9%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$60.35
Day Range$58.83 - $60.46
Avg. Volume (3M)1.5M
Market Cap$5.4B
52 Week Range
$22.59$68.73
Next EarningsIn 28 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$169.5M100%
Gross Profitminus cost of goods$167.4M99%
Operating Incomeminus R&D and overhead$3.9M2%

In plain terms: out of every $100 in revenue, Travere Therapeutics, Inc. currently loses $21.

Fundamentals & Financials

Revenue (TTM)
$591.3M
Net Income (TTM)
-$43.4M
EPS (TTM)
-$0.45
ROA (TTM)
-5.44%
Current Ratio
4.05

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

0.0%Q1 2026$0.03
-30.0%Q2 2026-$0.39
-174.8%Q3 2026-$0.37
Next

Oct 29

in 28 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -174.8%

Travere Therapeutics’ preliminary second fiscal quarter of 2026 results, reported August 4, showed revenue topping consensus as sales rose 48.2% year over year to roughly $169.6 million (up from $114.4 million a year ago). Revenue of $169.6 million topped the $157.3 million estimate, +7.8%. Profitability in the quarter was reflected in gross profit of about $167.4 million, translating to a gross margin of roughly 99%. The company generated operating cash flow of around $58.1 million. For the next period, consensus calls for EPS of $0.03 on revenue of $195.2 million.

Next report — what to expect

Travere Therapeutics, Inc. (TVTX) reports on October 29, 2026. The next-period consensus calls for EPS of $0.03 on revenue of $195.7 million. For trailing context, revenue rose +48.2% year over year last quarter. TVTX has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing and commercializing therapies for rare kidney and metabolic diseases, with $490.7 million in revenue in FY2025. Its business centers on specialty medicines for small patient populations, led by FILSPARI for rare kidney disorders and Thiola-based treatments for cystinuria.

Name
Travere Therapeutics, Inc.
CEO
Eric Dube
Website
www.travere.com
Industry
Healthcare
Employees
497

Today's Snapshot

AI-generated

TVTX closed 1.9% lower at 58.86, in line with a weaker sector. Travere Therapeutics executives face an investigation over possible self-dealing harming shareholders.

Trading Volume

Below 10d avg (1.7M)

1.5M

vs S&P 500 Today

Underperforming Market

-2.07%

Updated: September 30, 2026 at 20:12 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
TVTX is graded a sell as short-term weakness contrasts with longer-term support, with near-term moving averages trading above the current price of 58.88 while the 100‑ and 200‑day averages remain well below, suggesting longer-run strength but present downward pressure. Momentum indicators including MACD and CCI are negative and ADX around the high 20s implies a modestly trending move, while OBV is negative, signaling selling interest. ATR is moderate and the classic pivot sits above the market, highlighting resistance near current levels. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$47.15 - $62.23
    Sell
  • RSI (14)39.01
    Neutral
  • Stochastic %K (14, 3, 3)17.55
    Buy
  • MACD Level (12, 26)-1.02
    Sell

Peers & Related Assets

APGEApogee Therapeutics, Inc.
$135.07-0.0%
CGONCG Oncology Inc.
$70.89+0.5%
CELCCelcuity Inc.
$79.52+2.8%
XENEXenon Pharmaceuticals Inc.
$37.19-0.2%
TARSTarsus Pharmaceuticals, Inc.
$78.61+2.5%
IRONDisc Medicine, Inc.
$65.46-0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.